Clinical practice guidelines on prostate cancer screening using the PSA test have clearly recommended that clinicians practice shared decision making - a process involving clinician-patient discussion of the pros, cons, and uncertainties of screening. The gene discussed is KLK3; the disease is prostate cancer.